Pure manipulation.....we will get over this next week and sky rocket after earnings. The new sales strategy is clearly working well. This will drive the earnings
WE HAVE TO GET THROUGH THIS WEEK WITH THE USUAL MM MANIPULATION. THE WEEK AFTER WILL START TO ANTICIPATE THE FOLLOWING WEEK'S EARNINGS AND THE CC -- NOT THAT THE EARNINGS WILL BE THE FOCUS. HOPEFULLY THIS CAN GET BACK OVER TWO FOR THE CC.
Aug 1st we rise ARLZ
Zontivity gains traction.
Why It dropped today?
KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.
Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.
So nobody really knows squat......me included.......but it's not stopping individuals from educating us.
NEVER NEVER --TRY TO CATCH A FALLING KNIFE IMO...DEAD CAT BOUNCE COMING ?? OR GOING LOWER. ONE THING FOR SURE THE M & M'S ALWAYS SEEM TO WIN... 115 FOR SUPPORT ?? OR LOWER ? ALL OPINION NOT FINANCIAL ADVICE... GL TO ALL..
and the good news keeps coming. 6-15 the short volume was 5.7 mil and the new 6-30 volume is 3.5 mil . it looks like the shorts are leaving which should take the pressure off of the pps. given the price rise of the last 2 weeks I presume that a lot of the others are starting to close as well. given a positive quarterly report in august we can get back to the 3's on our way to 4 to 5 by year end.
The sales volume picked up with the new pricing strategy. Expect this go to $3 after earnings report.
Somebody knows something. Nice volume to the upside.
BO target!!! Not hear from me but it's going to hit $10.00 very soon.
A key new data point in the Zacks summary yesterday is that NRx for week ended 23 June exceeded the highest during the Merck promotion period. So, traction is being made.
Also, weekly TRx is approaching 250---implying a monthly run-rate of 1000.
However, the monthly rate needs to get to 10,000 over the next 12 months to meet the Bloom Burton view of about $40M in revenue from Zontivitiy sales in 2018.
A ways yet to go---but the sort of encouraging!
the phased launch was very successful with 98% growth in new prescriptions (NRx) after five weeks, compared to the five weeks preceding the phased launch.
Hey you traders...This could drop on profit taking by .20 or more..IMO - not financial advice. COULD? The M & M's hold all the cards IMO.
Bloom Burton Review from April 2017:
Upgrading ARLZ to BUY (Speculative) Following Sharp Sell-Off - Zontivity the Key Reason to Own at this Level Last Wednesday, Aralez announced prudent cost cuts, but ARLZ stock went down.....a lot, dropping 25% over Wednesday and Thursday - that on top of a 69% decline from its peak last fall. Following the sell-off, we believe the long-term risk/reward has become attractive, and as a result, we are raising our rating to BUY (was ACCUMULATE), Speculative Risk. Maintaining price target of $5.00 based on probability-weighting of DCF valuations for base case, upside and downside scenarios. Highlights Yes, Yosprala’s anemic launch precipitated the cost cuts, but we already knew Yosprala was doing poorly. There are other business risks too: Aralez partner Horizon (NASDAQ:HZNP; unrated) is nearing the end of patent litigation for Vimovo (ARLZ 2016 revenues: $20 MM – we estimate a 30% risk that ARLZ will face a generic Vimovo in 2017); Veterans Affairs may exit a supply agreement for Toprol (which, we estimate, would reduce Aralez’s annual revenues for that product from ~$100 MM to $70-$80 MM); Zontivity may fall flat. And yes, ARLZ has a load of debt ($274 MM at YE-2015). However, none is due until 2022, and with the announced cost cuts, we believe the company can reach positive cash flow if the Zontivity re-launch is successful. The company has deep-pocketed backers who hold both equity and debt, and who have experienced multiple prior successes with the Aralez management team. We believe this group is likely to have the patience to see the Zontivity story play out. If we consider a worst case scenario (Vimovo generic in 2017; VA drops Toprol; Zontivity peaks at $20 MM annual sales), we estimate the liquidation value of the company’s assets to be $261 MM which, after subtracting the $245 MM of forecast YE-2017 net debt, doesn’t leave much for equity holders ($0.25 per share by our calculation – our downside valuation scenario). But, we think Zontivity (vorapaxar) is a hidden gem – it is the only second generation platelet inhibitor with positive outcome data and approval for peripheral arterial diseases (PAD), which affects ~8.5 MM people in the United States. Our base case model forecasts peak Zontivity sales of $363 MM in the U.S. and Canada in 2023 (10% penetration in the severe PAD population), which supports a base case DCF valuation of $4.98 per ARLZ share. An upside scenario (Zontivity peaking at 15% penetration) generates a 2023 sales estimate of $545 MM, and an upside DCF valuation of $9.17 per ARLZ share. This does not include the possibility that, as cardiologists become more comfortable with Zontivity, the drug could also see increased use in triple therapy in patients with acute coronary syndrome. And, although it seems a stretch right now, Yosprala might get a boost as Zontivity opens doors to more cardiologists. We plan to keep an eye on the Vimovo litigation, and the VA decision, but with ARLZ at $1.61, we believe that downside risks around those events are mostly/all priced-in, with upside likely if the Zontivity re-launch goes as planned.
Monster Microcaps Alert to ARLZ shareholders. Clean Energy Technologies - CETY - price today $.018. Price target $.20 by year end. Clean Energy Technologies. CETY recently announced expansion with their Europe Sales and Service Center for Europe new sales and to serve 65 existing customers with CETY’s General Electric clean energy Heat Recovery Systems and just announced they have already sold the first of SEVERAL HUNDRED units to come SOON.
Each CETY Heat Recovery System sells for $300,000 and market demand is several BILLION DOLLARS.
CETY purchased Heat Recovery Systems Division from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million annual sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.
Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
Bloom Burton sees, as a plausible scenario, that Zontivity will generate peak US+Canada revenues of near $400M by 2023.
That is assuming a 10% market share for the severe PAD patient sector alone.
They see a $43M sales of Zontivity in 2018.
It should be clear by 2H2017 if the sales are ramping toward such a platform.
The drug is estimated to cost $3600/yr per patient in the US (half that in Canada)
•We’re interviewing an interventional cardiologist whose research focuses on defining the effects of antiplatelet agents, antiplatelet agent development, and understanding the relation of platelet reactivity to ischemic event occurrence.
•The call will take place Wednesday, July 12th at 3:00pm ET.
•The overall goal of this interview is to compare the efficacy and potential patient populations of Zontivity (vorapaxar) and Yosprala (omeprazole and aspirin) in the cerebrovascular and cardiovascular event market.
•Topics such as drawbacks of prescribing the two drugs, progress thus far in the space, and expected roles of each in the clinical setting will be discussed.
With Merck (MRK) recently divesting Zontivity to Aralez Pharmaceuticals (ARLZ), adding to their cardio health portfolio, Yosprala and Zontivity are now set to enter a similar market in cerebrovascular and cardiovascular events. Slingshot Insights will be hosting an expert call to compare the two products on Wednesday July 12th at 3pm ET. We’ll discuss the drugs' mechanism of action and efficacy compared to other treatments on the market, side effect profiles, and payor reimbursement with a Key Opinion Leader. "